CASE PRESENTATION {#s1}
=================

A former full-term, 2-mo-old Caucasian male presented with tachypnea, pallor, an otherwise normal physical exam, and severe anemia (hemoglobin \[Hb\] 1.5 g/dl, mean corpuscular volume \[MCV\] 91.8 fl, and reticulocyte level 0.5%). White blood cell and platelet counts were normal. Direct and indirect Coombs tests were negative. Renal function was normal. Anemia persisted after several red blood cell transfusions. Bone marrow biopsy at age 6 mo showed 80%--90% cellularity with marked erythroid hypoplasia, consistent with congenital pure red cell aplasia (Diamond--Blackfan anemia \[DBA\]), which is most commonly caused by autosomal dominant mutations in one of 17 ribosomal protein (RP) genes ([@MCS003384CLAC8]). Commercial genetic testing using Sanger sequencing identified a heterozygous *RPS17* intronic variant of uncertain significance (VUS) that was not predicted to alter splicing by two prediction tools. No pathogenic mutations or VUSs were identified in *RPL5, RPL11, RPL19, RPL26, RPL35a, RPS7, RPS10, RPS19, RPS24*, or *RPS26*.

Corticosteroid therapy, which stimulates erythropoiesis in some *RP* or *GATA1* gene--mutated DBA patients, did not improve the anemia in the current patient, and chronic RBC transfusions were continued. At 2 yr of age, he developed atopic dermatitis, anti-D and anti-E warm auto anti-RBC antibodies, and transfusion-related iron overload treated with subcutaneous deferoxamine. At 5 yr of age, he developed widespread molluscum contagiosum and laboratory signs of autoimmune neutropenia including absolute neutrophil counts (ANCs) fluctuating between 0 and 300/mm^3^ and bone marrow myeloid hyperplasia with neutrophil precursor arrest at the band stage. After multiple bouts of fever and neutropenia, granulocyte colony stimulating factor (G-CSF) was initiated, with an increase in ANC to 700--2000/mm^3^. Plasma immunoglobulin levels were in the low-normal range. Relevant laboratory data are summarized in [Table 1](#MCS003384CLATB1){ref-type="table"}.

###### 

Laboratory data

                                                              Presentation   Age 2                Age 5                        Age 6
  ----------------------------------------------------------- -------------- -------------------- ---------------------------- --------------------
  Hgb (g/dl)                                                  1.5            11.5 (transfused)    8 (transfusion trough)       10.1 (transfused)
  MCV (fl)                                                    91.8           82.8 (transfused)    82.4 (transfusion trough)    84.7 (transfused)
  Reticulocyte percent                                        0.50%          0.21% (transfused)   0.12% (transfusion trough)   0.29% (transfused)
  WBC (per mm^3^)                                             12,900         6500                 2900                         4600
  ANC (per mm^3^)                                             6800           1400                 0                            700
  Platelets (per mm^3^)                                       364,000        343,000              219,000                      178,000
  IgG (mg/dl)                                                                                     665                          727
  IgM (mg/dl)                                                                                     100                          42
  IgA (mg/dl)                                                                                     45                           59
  RBC antibody screen                                         Negative       Positive             Positive                     Positive
  Neutrophil antibody                                                                             Positive                     
  Ferritin (ng/mL)                                            762            2008                 2315                         2828
  R2\* Estimated liver iron content (mg Fe/gram dry weight)                  10.86                3.67                         8.22
  Plasma ADA2 activity                                                                                                         0.4 mU activity/ml

TECHNICAL ANALYSIS AND VARIANT INTERPRETATION {#s2}
=============================================

The patient and parents were tested by CLIA-approved commercial whole-exome sequencing (WES) with targeted analysis of 429 candidate genes associated with the Human Phenotype Ontology ([@MCS003384CLAC12]) terms "Anemia (HP:0001903)," "Bone marrow hypocellularity (HP:0005528)," "Congenital neutropenia (HP:0005549)," and "Neutropenia (HP:0001875)" at 20× coverage depth or greater. We also performed whole-genome sequencing (WGS) under the research protocol "Investigation of the Genetics of Hematologic Diseases" (INSIGHT-HD, NCT 02720679).

The WES identified a heterozygous paternally inherited mutation in the *CECR1* gene (p.His112Gln), which encodes adenosine deaminase 2 (ADA2) ([Fig. 1](#MCS003384CLAF1){ref-type="fig"}A; [Table 2](#MCS003384CLATB2){ref-type="table"}). Mutations in *CECR1* lead to reduced levels of ADA2, a secreted extracellular regulator of adenosine signaling and modulator of cell proliferation and differentiation ([@MCS003384CLAC3]). This variant is present in the gnomAD population database at a frequency of 0.002% (5/245816 alleles) and was reported in a pediatric patient with early-onset polyarteritis nodosum and ADA2 deficiency ([@MCS003384CLAC9]). Because biallelic *CECR1* mutations were recently reported to cause hypoplastic anemia ([@MCS003384CLAC13]; [@MCS003384CLAC3]), we investigated the possibility of a second mutation in our patient, initially by investigating plasma ADA2 activity, which was found to be very low at 0.4 mU/ml (normal 13.9 ± 5.3). Review of WGS data confirmed the *CECR1* missense mutation p.His112Gln in the patient and father. Visual analysis of read depth and mate--pair mapping information revealed compelling evidence for a *CECR1* exon 7 deletion in the patient and mother ([Fig. 1](#MCS003384CLAF1){ref-type="fig"}B; [Table 2](#MCS003384CLATB2){ref-type="table"}). Because the left deletion breakpoint occurred in a region of repetitive DNA ([Fig. 1](#MCS003384CLAF1){ref-type="fig"}C), which can interfere with analytical algorithms for WGS, it was initially filtered away by a quality-control step designed to reduce false-positive rates. A similar deletion was reported previously in an ADA2-deficient family ([@MCS003384CLAC13]).

![Congenital hypoplastic anemia caused by compound heterozygosity for a *CECR1* missense mutation and exon 7 deletion. (*A*) Pedigree. (*B*) Plot of WGS coverage depth on Chromosome 22p of the proband suggests an ∼2-kb maternally inherited *CECR1* deletion (black arrows). (*C*) Visualization of mapped reads of the proband (via the Integrated Genomics Viewer) in the region of the deletion event. The red arrow denotes the position of the right breakpoint. CECR1 exon 7 and *Alu* repeat sequences are shown at the *bottom* in blue. Colored reads indicate pairs with anomalous insert sizes or reads with a mate mapping to a repetitive sequence on another chromosome. Dark red reads indicate a deletion event. The left breakpoint is embedded in repetitive *Alu*-derived sequences and thus was identified by only two of the four calling algorithms used. Failure to precisely define the breakpoint locations caused this copy-number variant to be filtered away by a quality-control step in our standard analytical pipeline for WGS.](MCS003384Cla_F1){#MCS003384CLAF1}

###### 

Genomic findings

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gene      Genomic location                                                       HGVS cDNA        HGVS protein        Zygosity       Parent of origin   Variant interpretation
  --------- ---------------------------------------------------------------------- ---------------- ------------------- -------------- ------------------ ------------------------
  *CECR1*   Chr 22: 17207277 (GRCh38)\                                             NM_017424\       p.His112Gln         Heterozygous   Father             Pathogenic
            Chr 22: 17688167 (GRCh37)                                              c.336C\>G\                                                             
                                                                                   NM_001282227\                                                          
                                                                                   c.210C\>G                                                              

  *CECR1*   Chr 22: *CECR1* deletion, ∼2 kb spanning exon 7; breakpoints unknown   NM_001282227\    p.Asp319GlyfsTer6   Heterozygous   Mother             Pathogenic
                                                                                   c.956-1113 del                                                         
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Variant interpretation: ADA2 deficiency is an autosomal recessive condition caused by biallelic loss-of-function mutations in the *CECR1* gene. The His112Gln variant was reported previously in a patient with ADA2 deficiency ([@MCS003384CLAC9]). The *CECR1* exon 7 deletion causes a frameshift mutation with premature translational termination. The proband is a compound heterozygote for the paternal and maternal *CECR1* mutant alleles and has minimal circulating ADA2 activity. Hence, both mutations are pathogenic.

Although WES is highly sensitive for capturing nucleotide substitutions, this approach does not capture all deletions. However, in light of the new findings, the commercial laboratory reevaluated the WES data, identified reduced read depth for *CECR1* exon 7 in the patient and mother, and confirmed a heterozygous deletion via next-generation sequencing (NGS). Together, persistent investigation and multiple complementary laboratory approaches converged to the diagnosis of hypoplastic "DBA-like" anemia caused by compound heterozygous *CECR1* mutations with ADA2 deficiency.

Germline biallelic *CECR1* mutations with ADA2 deficiency causing recurrent fever, vasculopathy, and stroke were first described in 2014 ([@MCS003384CLAC9]; [@MCS003384CLAC14]). Subsequent reports identified hematological manifestations including hypoplastic anemia, autoimmune cytopenias, and immunodeficiency in some patients ([@MCS003384CLAC13]; [@MCS003384CLAC4]). The pathophysiology of ADA2 deficiency and reasons for the clinical variability of this syndrome are unknown. Treatment includes supportive care and immunosuppression ([@MCS003384CLAC1]; [@MCS003384CLAC3]). A recent study treating 14 ADA2-deficient patients with allogeneic hematopoietic stem cell transplantation reported resolution of all disease-associated pathologies with no deaths ([@MCS003384CLAC5]).

SUMMARY {#s3}
=======

Approximately 70% of DBA cases are caused by autosomal dominant mutations in multiple RP genes. Congenital hypoplastic anemia also occurs less frequently with mutations in *GATA1* (X-linked), *TSR2* (X-linked), *EPO* (autosomal recessive), and *CECR1* (autosomal recessive) ([@MCS003384CLAC3]; [@MCS003384CLAC13]; [@MCS003384CLAC2]; [@MCS003384CLAC6]). Obtaining a genetic diagnosis is important for counseling, therapeutic decisions, and reassurance to patients, families, and clinicians. The clinical manifestations of ADA2 deficiency are heterogenous and can include autoimmunity, immunodeficiency, vasculitis, stroke, and erythroid hypoplasia ([@MCS003384CLAC1]; [@MCS003384CLAC4]). Thus, the genetic diagnosis of biallelic *CECR1* mutations with ADA2 deficiency explained our patient\'s severe eczema and immune cytopenias, which are atypical for RP-haploinsufficient DBA.

This case illustrates several important principles of genetic testing for rare blood disorders. *First*, mutations in different genes (characterized and uncharacterized) can produce similar phenotypes (i.e., locus heterogeneity). Our patient was initially assigned a clinical diagnosis of DBA, with no mutations detected in classical DBA genes. Subsequent testing identified biallelic mutations in *CECR1* ([Table 2](#MCS003384CLATB2){ref-type="table"}), which was linked to hypoplastic anemia only recently. *Second*, genomic sequencing tests have limitations ([@MCS003384CLAC10]). In this case, valid technical issues associated with WES and WGS interfered initially with detection of a 2-kb *CECR1* deletion. Genome-wide array analysis such as comparative genome hybridization (CGH) or single-nucleotide polymorphism (SNP) array had not been performed in this patient. However, the commercially available array platforms would very likely miss the small intragenic one-exon deletion because of the low resolution that is inherent to such methods. Multiplex ligation--dependent probe amplification (MLPA), considered to be the gold standard for identification of small intragenic deletions, was not available for the *CECR1* gene. *Third*, diagnostic WES or WGS frequently detect multiple VUSs in the same individual; pinpointing relevant disease alleles requires clinical expertise and consideration of data supporting variant pathogenicity ([@MCS003384CLAC11]). *Finally*, our understanding of inherited blood disorders and technologies to detect the underlying gene mutations is progressing rapidly. WGS is the most comprehensive approach, but it is more expensive and technically challenging than WES ([@MCS003384CLAC7]). Both methods typically interrogate a candidate gene panel, which may not include newly identified disease-associated genes. Thus it is important to periodically revisit phenotype-based genetic testing options, which are seldom all-inclusive and likely to evolve in parallel with new scientific discoveries. Five years after initial presentation, reevaluation of the progressive phenotype of our patient, combined with advances in genomics and gene discovery, provided a definitive genetic diagnosis.

Overall, this case illustrates the utility of genetic testing for rare blood disorders and the requirements for multidisciplinary expertise and persistence to optimize success in difficult cases. More specifically, ADA2 deficiency caused by biallelic *CECR1* mutations should be considered for all cases of congenital hypoplastic anemia without RP gene haploinsufficiency.

ADDITIONAL INFORMATION {#s4}
======================

Data Deposition and Access {#s4a}
--------------------------

The genomic variants were submitted to ClinVar (<https://www.ncbi.nlm.nih.gov/clinvar/>) and can be found under accession numbers SCV000854421 (missense) and SCV000854422 (deletion). The raw sequencing data has been submitted to dbGaP (<https://www.ncbi.nlm.nih.gov/gap>), accession number pending.
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